Literature DB >> 21652068

First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia.

A O Odibo1, Y Zhong, K R Goetzinger, L Odibo, J L Bick, C R Bower, D M Nelson.   

Abstract

OBJECTIVE: To test the hypothesis that a combination of PP13, PAPP-A and first-trimester uterine artery Doppler would improve the prediction of pre-eclampsia.
METHODS: This is a prospective cohort study of pregnant women followed from the first-trimester to delivery. PP13 and PAPP-A were determined by immunoassay of maternal serum at 11-14 weeks', when uterine artery Doppler measurements were assessed. Cases identified with any form of pre-eclampsia were compared with a control group without pre-eclampsia. The sensitivity of each marker or their combinations in predicting pre-eclampsia for different fixed false positive rates was calculated from the ROC curves.
RESULTS: Forty two women were diagnosed with pre-eclampsia and 410 women with pregnancies not complicated by pre-eclampsia were used as controls. For a fixed false positive rate (FPR) of 20%, PP13, PAPP-A and mean uterine artery pulsatility index identified 49%, 58% and 62% respectively, of women who developed any form of pre-eclampsia. PP13 was best in predicting early onset pre-eclampsia with a sensitivity of 79% at a 20% FPR. Combinations of the three first-trimester assessments did not improve the prediction of pre-eclampsia in later pregnancy.
CONCLUSION: First-trimester PP13, PAPP-A and uterine artery PI are reasonable, individual predictors of women at risk to develop pre-eclampsia. Combinations of these assessments do not further improve the prediction of pre-eclampsia.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21652068      PMCID: PMC3142303          DOI: 10.1016/j.placenta.2011.05.006

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  20 in total

Review 1.  Pathogenesis and genetics of pre-eclampsia.

Authors:  J M Roberts; D W Cooper
Journal:  Lancet       Date:  2001-01-06       Impact factor: 79.321

Review 2.  Prenatal screening, epidemiology, diagnosis, and management of preeclampsia.

Authors:  Deirdre J Lyell; Geralyn M Lambert-Messerlian; Linda C Giudice
Journal:  Clin Lab Med       Date:  2003-06       Impact factor: 1.935

Review 3.  Stereology and the placenta: where's the point? -- a review.

Authors:  T M Mayhew
Journal:  Placenta       Date:  2006-01-05       Impact factor: 3.481

4.  Evaluation of logistic regression reporting in current obstetrics and gynecology literature.

Authors:  Rafael T Mikolajczyk; Alexis DiSilvestro; Alexis DiSilvesto; Jun Zhang
Journal:  Obstet Gynecol       Date:  2008-02       Impact factor: 7.661

5.  First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia.

Authors:  K Spencer; N J Cowans; I Chefetz; J Tal; H Meiri
Journal:  Ultrasound Obstet Gynecol       Date:  2007-02       Impact factor: 7.299

6.  Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A.

Authors:  L S Laursen; M T Overgaard; R Søe; H B Boldt; L Sottrup-Jensen; L C Giudice; C A Conover; C Oxvig
Journal:  FEBS Lett       Date:  2001-08-24       Impact factor: 4.124

7.  Functional analyses of placental protein 13/galectin-13.

Authors:  Nandor G Than; Elah Pick; Szabolcs Bellyei; Andras Szigeti; Ora Burger; Zoltan Berente; Tamas Janaky; Arpad Boronkai; Harvey Kliman; Hamutal Meiri; Hans Bohn; Gabor N Than; Balazs Sumegi
Journal:  Eur J Biochem       Date:  2004-03

8.  Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia.

Authors:  Kevin Spencer; Nicholas J Cowans; Kypros H Nicolaides
Journal:  Prenat Diagn       Date:  2008-01       Impact factor: 3.050

9.  First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction.

Authors:  Ilana Chafetz; Ido Kuhnreich; Marei Sammar; Yossi Tal; Yair Gibor; Hamutal Meiri; Howard Cuckle; Myles Wolf
Journal:  Am J Obstet Gynecol       Date:  2007-07       Impact factor: 8.661

10.  A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound.

Authors:  K H Nicolaides; R Bindra; O M Turan; I Chefetz; M Sammar; H Meiri; J Tal; H S Cuckle
Journal:  Ultrasound Obstet Gynecol       Date:  2006-01       Impact factor: 7.299

View more
  27 in total

Review 1.  First trimester screening for pre-eclampsia.

Authors:  Stefan C Kane
Journal:  Obstet Med       Date:  2016-05-14

Review 2.  Comparative risks and predictors of preeclamptic pregnancy in the Eastern, Western and developing world.

Authors:  Ning Zhang; Jing Tan; HaiFeng Yang; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2020-09-25       Impact factor: 5.858

3.  Prediction and prevention of hypertensive disorders of pregnancy.

Authors:  Akihide Ohkuchi; Chikako Hirashima; Kayo Takahashi; Hirotada Suzuki; Shigeki Matsubara
Journal:  Hypertens Res       Date:  2016-08-18       Impact factor: 3.872

4.  Placental pathology, first-trimester biomarkers and adverse pregnancy outcomes.

Authors:  A O Odibo; K R Patel; A Spitalnik; L Odibo; P Huettner
Journal:  J Perinatol       Date:  2014-01-16       Impact factor: 2.521

Review 5.  Hypertension in pregnancy.

Authors:  Amanda R Vest; Leslie S Cho
Journal:  Curr Atheroscler Rep       Date:  2014-03       Impact factor: 5.113

6.  Molecular determinants of microvascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Wentao Yu; Wei Gao; Dan Rong; Zhixian Wu; Raouf A Khalil
Journal:  Microcirculation       Date:  2018-10-19       Impact factor: 2.628

7.  Development and validation of a risk factor scoring system for first-trimester prediction of preeclampsia.

Authors:  Katherine R Goetzinger; Methodius G Tuuli; Alison G Cahill; George A Macones; Anthony O Odibo
Journal:  Am J Perinatol       Date:  2014-04-04       Impact factor: 1.862

8.  First trimester serum analytes, maternal characteristics and ultrasound markers to predict pregnancies at risk for preterm birth.

Authors:  M J Stout; K R Goetzinger; M G Tuuli; A G Cahill; G A Macones; A O Odibo
Journal:  Placenta       Date:  2012-11-28       Impact factor: 3.481

9.  Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis.

Authors:  John Allotey; Kym Ie Snell; Melanie Smuk; Richard Hooper; Claire L Chan; Asif Ahmed; Lucy C Chappell; Peter von Dadelszen; Julie Dodds; Marcus Green; Louise Kenny; Asma Khalil; Khalid S Khan; Ben W Mol; Jenny Myers; Lucilla Poston; Basky Thilaganathan; Anne C Staff; Gordon Cs Smith; Wessel Ganzevoort; Hannele Laivuori; Anthony O Odibo; Javier A Ramírez; John Kingdom; George Daskalakis; Diane Farrar; Ahmet A Baschat; Paul T Seed; Federico Prefumo; Fabricio da Silva Costa; Henk Groen; Francois Audibert; Jacques Masse; Ragnhild B Skråstad; Kjell Å Salvesen; Camilla Haavaldsen; Chie Nagata; Alice R Rumbold; Seppo Heinonen; Lisa M Askie; Luc Jm Smits; Christina A Vinter; Per M Magnus; Kajantie Eero; Pia M Villa; Anne K Jenum; Louise B Andersen; Jane E Norman; Akihide Ohkuchi; Anne Eskild; Sohinee Bhattacharya; Fionnuala M McAuliffe; Alberto Galindo; Ignacio Herraiz; Lionel Carbillon; Kerstin Klipstein-Grobusch; SeonAe Yeo; Helena J Teede; Joyce L Browne; Karel Gm Moons; Richard D Riley; Shakila Thangaratinam
Journal:  Health Technol Assess       Date:  2020-12       Impact factor: 4.014

10.  Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects.

Authors:  Rolf Becker; Thomas Keller; Holger Kiesewetter; Heiner Fangerau; Uta Bittner
Journal:  Arch Gynecol Obstet       Date:  2013-02-07       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.